Shares of Xeris Pharmaceuticals XERS rose 1.8% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 66.29% year over year to ($0.30), which beat the estimate of ($0.34).
Revenue of $8,051,000 rose by 350.28% from the same period last year, which beat the estimate of $7,470,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Xeris Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: May 13, 2021
Time: 08:30 AM
ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action
Price Action
Company's 52-week high was at $7.94
Company's 52-week low was at $2.45
Price action over last quarter: down 21.89%
Company Description
Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
